Fibroblasts neurotrophin signaling sustains pathological vascular maturation in rheumatoid arthritis.

The core observation — that mural cell coverage and arterial/capillary vascular structures persist and apparently expand in RA synovium after six months of csDMARD or TNFi therapy, and that a NOTCH3→NGF→NGFR/TRK axis can drive fibroblasts toward mural-cell marker programs — is interesting, internally consistent across five methodologically independent approaches, and translationally actionable. The ethics and compliance record is clean. What lowers readiness is not the plausibility of the model but three specific places where the stated conclusions run ahead of the evidence presented, each of which requires reanalysis or an additional control rather than rewording alone: (i) the headline "persistence despite treatment" claim is expressed in normalized units whose denominator plausibly changes with treatment, and the absolute-count analysis that would settle it is not shown; (ii) the explant TRK-inhibitor result — the basis for the therapeutic framing — reports a ~50% reduction in PECAM1⁺ structures with no viability or apoptosis control, so tissue toxicity is not excluded; (iii) the word "differentiation" in the title and throughout describes marker convergence and modest contractility, not fate. Reproducibility is further limited by absent sample sizes, no data or code deposition, an undocumented bulk RNA-seq pipeline that underpins the 461-gene signature, and three concrete citation errors. None of these is fatal. The denominator issue is answerable by reanalysing data the authors already hold; the viability control is a single short experiment on material and models they have running; the differentiation language can be scaled to the evidence or supported with a trajectory analysis of existing data. Because at least one required item (absolute-density reanalysis) has an outcome that could change a conclusion, and one (explant viability) requires new data, this is a major revision rather than a long minor one. I would expect a revised version to be a strong paper.

Readiness measures the current manuscript. Novelty, significance, and usefulness are shown separately. The recommendation follows the work required for publication, not a score range.